FDA giving White House new guidance on rapid COVID-19 test

WASHINGTON — The head of the Food and Drug Administration said Friday his agency has provided new guidance to the White House after data suggested that a rapid COVID-19 test used by President Donald Trump and others every day may provide inaccuracies and false negatives.

Commissioner Steve Hahn said that if a person is suspected of having the disease caused by the coronavirus, “it might be worth, if the test is negative, getting a second confirmatory test. That's what our guidance is about.”

The test, by Abbott Laboratories, is used daily at the White House to test

Trump and key members of his staff, including the coronavirus task force.

The FDA said late Thursday it was investigating preliminary data suggesting the 15-minute test can miss COVID- 1 9 cases, false ly clearing infected patients.

Hahn, asked on CBS on Friday whether he'd continue to recommend using the test at the White House, said, “That will be a White House decision.” But he said the test is on the market and the FDA continues to “recommend its use or to have it available for use.”

Federal health officials have been alerting doctors to the potential inaccuracy in the test, which is used at thousands of hospitals, clinics and testing sites across the United States.

The FDA warning came a day after researchers at New York University reported results suggesting Abbott's test can miss up to half the infections caught by a rival test made by Cepheid.

The research has not been peer-reviewed or published in a medical journal and was based on about 100 patients.

The researchers found that Abbott's test, run on the company's portable ID NOW system, missed onethird of the infections caught by Cepheid' st est when swabs were stored in liquid used to transport laboratory samples.

When the samples were kept dry the test missed 48% of the cases flagged by Cepheid's test.